
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Adenylate cyclase 9/AC9/ADCY9 CRISPR/Cas9 KO Plasmid (m) | sc-418999 | 20 µg | $397.00 |
Adcy9 encodes adenylate cyclase 9 (AC9/ADCY9), a membrane-associated enzyme that converts ATP to cAMP in response to GPCR-linked signaling, shaping compartmentalized second-messenger dynamics. AC9-derived cAMP regulates protein kinase A and EPAC-dependent pathways that influence phosphorylation networks, gene transcription, ion transport, and metabolic adaptation. In mouse cells, ADCY9 activity contributes to stimulus-specific signaling outputs and cross-talk with calcium- and G protein–mediated processes. Dysregulated cAMP signaling and altered ADCY9 function have been associated with phenotypes relevant to cardiometabolic regulation, airway biology, and neurobehavioral pathways, making Adcy9 a useful node for mechanistic studies of signal transduction.
Adenylate cyclase 9/AC9/ADCY9 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Adcy9 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Adcy9 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Adcy9 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Adenylate cyclase 9/AC9/ADCY9 protein expression.
This CRISPR knockout system enables efficient generation of Adcy9-deficient cell models for investigation of Adenylate cyclase 9/AC9/ADCY9 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.